Vertex Pharmaceuticals Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Vertex Pharmaceuticals Inc in the second quarter 2026?
Vertex Pharmaceuticals Inc achieved a return on average equity (ROE) of 23.31 % in its second quarter 2026, this is above VRTX's average return on equity of -1.69%.
Vertex Pharmaceuticals Incs equity during the 12 months ending in the second quarter 2026 are valued at $18 billion

ROE fell compared to the first quarter 2026, despite the net income growth of 6.63% from the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 33 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 487 to 549.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	17.89 %	17.37 %	13.75 %	10.8 %	-
Y / Y Net Income Change	6.48 %	59.59 %	30.46 %	3.59 %	-
Net Income (TTM) in Millions	4,405	4,338	3,953	3,675	3,638
Return On Equity (TTM)	23.31 %	23.93 %	22.7 %	21.81 %	22.14 %
VRTX's Total Ranking	# 549	# 487	# 406	# 467	# 477
Equity (TTM) in Millions	20,248	19,362	18,666	17,319	17,175
Seq. Equity Change	4.58 %	3.73 %	7.78 %	0.83 %	4.12 %
Seq. Net Income Change	6.63 %	-13.41 %	9.99 %	4.84 %	59.82 %

Back to VRTX Management Effectiveness >> VRTX's 5 Years Annual ROE >> Compare VRTX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 34
Sector	# 73
Overall	# 549

Return On Equity Statistics
High	Average	Low
66.71 %	-1.69 %	-119.92 %
(Dec 31 2018)		(Jun 30 2011)

VRTX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	18,666	16,410	17,580	13,913	10,100
Y / Y Equity Change	13.75 %	-6.66 %	26.36 %	37.75 %	16.27 %
Net Income in Millions	3,953	-536	3,620	3,322	2,342
Y / Y Net Income Change	-	-	8.96 %	41.84 %	-13.63 %
Return On Equity	21.18 %	-3.26 %	20.59 %	23.88 %	23.19 %

Back to VRTX Management Effectiveness >> VRTX's 5 Years Annual ROE >> Compare VRTX ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 21.18 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VRTX's' Return on Equity at Yahoo Finance
VRTX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for VRTX's Competitors
Subscribers only: Roe for Vertex Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Equity for VRTX's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Aurinia Pharmaceuticals Inc	59.00 %
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %
Tenet Healthcare Corp	50.64 %
Nrc Health	48.29 %
Concentra Group Holdings Parent Inc	48.13 %
Bristol myers Squibb Company	46.65 %
Agilent Technologies inc	41.99 %
Eton Pharmaceuticals Inc	40.13 %
Adma Biologics Inc	39.59 %
Dexcom Inc	36.25 %
Transmedics Group Inc	33.37 %
Arcutis Biotherapeutics Inc	32.92 %
Caredx Inc	32.81 %
Zevra Therapeutics Inc	32.56 %
Acadia Pharmaceuticals Inc	32.39 %
Pro dex Inc	31.96 %
Protalix Biotherapeutics inc	31.61 %
Illumina Inc	31.08 %
Innoviva Inc	30.03 %
Phibro Animal Health Corporation	29.66 %
Chemed Corporation	29.45 %
Solventum Corporation	28.96 %
Pacs Group Inc	27.00 %
Sotera Health Company	26.75 %
Insulet Corporation	26.69 %
Bioventus Inc	25.96 %
Johnson and Johnson	25.74 %
Encompass Health Corporation	25.52 %
Resmed Inc	24.21 %

Date modified: 2026-09-02T20:09:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.